Literature DB >> 10594797

Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency.

B F Culleton1, M G Larson, P W Wilson, J C Evans, P S Parfrey, D Levy.   

Abstract

UNLABELLED: Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency.
BACKGROUND: Little is known about the prevalence of cardiovascular disease (CVD) and associated risk factors in individuals with mild renal insufficiency (RI). Furthermore, the long-term outcomes associated with mild RI in the community have not been described.
METHODS: Serum creatinine (SCr) was measured in 6233 adult participants of the Framingham Heart Study (mean age 54 years, 54% women). Mild RI was defined as SCr 136 to 265 micromol/liter (1.5 to 3.0 mg/dl) in men and 120 to 265 micromol/liter (1.4 to 3.0 mg/dl) in women. The lower limits for mild RI were defined by the sex-specific 95th percentile SCr values in a healthy subgroup of our sample. The upper limit for mild RI was chosen to exclude those subjects with more advanced renal failure. Cox proportional hazards analyses were used to determine the relationship of baseline RI to CVD and all-cause mortality.
RESULTS: At baseline, 8.7% of men (N = 246) and 8.0% of women (N = 270) had mild RI. Nineteen percent of the subjects with mild RI had prevalent CVD. During 15 years of follow-up, there were 1000 CVD events and 1406 deaths. In women, mild RI was not associated with increased risk for CVD events [hazards ratio (HR) 1.04, 95% CI, 0.79 to 1.37] or all-cause mortality (HR 1.08, 95% CI, 0.87 to 1.34). In men, mild RI showed no significant associations with CVD events (HR 1.17, 95% CI, 0.88 to 1.57), but it was associated with all-cause mortality in age-adjusted (HR 1.42, 95% CI, 1.12 to 1.79) and multivariable adjusted (HR 1.31, 95% CI, 1.02 to 1.67) analyses.
CONCLUSION: Mild RI in the community is common and is associated with a high prevalence of CVD. The association of RI with risk for adverse outcomes is strongly related to coexisting CVD and CVD risk factors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10594797     DOI: 10.1046/j.1523-1755.1999.00773.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  143 in total

1.  Cystatin C is associated with inflammation but not atherosclerosis in systemic lupus erythematosus.

Authors:  R Lertnawapan; A Bian; Y H Rho; P Raggi; A Oeser; J F Solus; T Gebretsadik; A Shintani; C M Stein
Journal:  Lupus       Date:  2011-11-09       Impact factor: 2.911

2.  Chronic kidney disease in octogenarians.

Authors:  Shani Shastri; Hocine Tighiouart; Ronit Katz; Dena E Rifkin; Linda F Fried; Michael G Shlipak; Anne B Newman; Mark J Sarnak
Journal:  Clin J Am Soc Nephrol       Date:  2011-04-21       Impact factor: 8.237

3.  Heart disease and stroke statistics--2011 update: a report from the American Heart Association.

Authors:  Véronique L Roger; Alan S Go; Donald M Lloyd-Jones; Robert J Adams; Jarett D Berry; Todd M Brown; Mercedes R Carnethon; Shifan Dai; Giovanni de Simone; Earl S Ford; Caroline S Fox; Heather J Fullerton; Cathleen Gillespie; Kurt J Greenlund; Susan M Hailpern; John A Heit; P Michael Ho; Virginia J Howard; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Diane M Makuc; Gregory M Marcus; Ariane Marelli; David B Matchar; Mary M McDermott; James B Meigs; Claudia S Moy; Dariush Mozaffarian; Michael E Mussolino; Graham Nichol; Nina P Paynter; Wayne D Rosamond; Paul D Sorlie; Randall S Stafford; Tanya N Turan; Melanie B Turner; Nathan D Wong; Judith Wylie-Rosett
Journal:  Circulation       Date:  2010-12-15       Impact factor: 29.690

4.  Glomerular filtration rate is related to severity of obstructive coronary artery disease in patients undergoing coronary angiography.

Authors:  Gholamreza Davoodi; Samira Mehrabi Pari; Mehrnaz Rezvanfard; Mahmood Sheikh Fathollahi; Manouchehr Amini; Elham Hakki; Ali Kazemisaeid; Ahmad Yaminisharif
Journal:  Int Urol Nephrol       Date:  2011-10-16       Impact factor: 2.370

Review 5.  Cardiac enzymes, renal failure and renal transplantation.

Authors:  Huseyin Bozbas; Aylin Yildirir; Haldun Muderrisoglu
Journal:  Clin Med Res       Date:  2006-03

Review 6.  Clinical imaging for prevention: directed strategies for improved detection of presymptomatic patients with undetected atherosclerosis--Part I: Clinical imaging for prevention.

Authors:  Leslee J Shaw; Daniel S Berman; Roger S Blumenthal; Matthew J Budoff; Tracy L Faber; Tauqir Goraya; Sandra S Halliburton; Harvey Hecht; Hosen Kiat; Wolfgang Koenig; Shaista Malik; Michael Merhige; Khurram Nasir; James K Min; James O'Keefe; Donna M Polk; Paolo Raggi; Jeffrey A Rosenblatt; Ronald G Schwartz; Allen J Taylor; Gregory S Thomas; William Wijns
Journal:  J Nucl Cardiol       Date:  2008 Jan-Feb       Impact factor: 5.952

Review 7.  Diabetic kidney disease and the cardiorenal syndrome: old disease, new perspectives.

Authors:  Ankur Jindal; Mariana Garcia-Touza; Nidhi Jindal; Adam Whaley-Connell; James R Sowers
Journal:  Endocrinol Metab Clin North Am       Date:  2013-08-01       Impact factor: 4.741

8.  Left ventricular mass progression despite stable blood pressure and kidney function in stage 3 chronic kidney disease.

Authors:  Michael E Seifert; Lisa de Las Fuentes; Charles Ginsberg; Marcos Rothstein; Dennis J Dietzen; Steven C Cheng; Will Ross; David Windus; Victor G Dávila-Román; Keith A Hruska
Journal:  Am J Nephrol       Date:  2014-05-06       Impact factor: 3.754

9.  Predominant effect of kidney disease on mortality in Pima Indians with or without type 2 diabetes.

Authors:  Meda E Pavkov; Peter H Bennett; Maurice L Sievers; Jonathan Krakoff; Desmond E Williams; William C Knowler; Robert G Nelson
Journal:  Kidney Int       Date:  2005-09       Impact factor: 10.612

10.  Long-term renal function and cardiovascular disease risk in obese kidney donors.

Authors:  Mohammad M Tavakol; Flavio G Vincenti; Hamid Assadi; Michael J Frederick; Stephen J Tomlanovich; John P Roberts; Andrew M Posselt
Journal:  Clin J Am Soc Nephrol       Date:  2009-05-14       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.